Cd4 Cd56 Hematodermic Neoplasm C1301363
A rare and aggressive blood cancer that typically appears as skin lesions but can spread to other organs. It mainly affects older adults and can involve the blood and bone marrow. Treatment usually involves chemotherapy and sometimes stem cell transplant.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- true
Sources and references
Authoritative medical sources used to create this content.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2022.
Bouard C, Boulanger V, Benet B, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical and therapeutic features. Br J Haematol. 2021;194(3):512-527.
Martin-Martin L, Lopez A, Vidal R, et al. Reduced-intensity stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a multicenter retrospective analysis. Blood. 2020;136(21):2415-2423.
Garner J, Chen K, Patel S, et al. Update on hematodermic neoplasm: from classification to treatment. Hematol Oncol. 2019;37(4):362-374.
Medication Comparisons
Compare medications used to treat Cd4 Cd56 Hematodermic Neoplasm C1301363. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy